Two monoclonal mouse antibodies with specificities for group B streptococcal capsular antigens were evaluated in assays for the identification of group B streptococci (GBS). One of these antibodies (A9) was shown to precipitate group B carbohydrate antigen in reactions with both purified group B antigen and antigen present in autoclave or enzyme extracts of GBS. A9 antibody was also specific for group B antigen in gel diffusion reactions with extracts of Lancefield group A, B, C, D, F, and G streptococci and was a highly sensitive reagent in detecting soluble group B antigen by counterimmunoelectrophoresis. Antigen extracted from all five serotypes of GBS was shown to be precipitated by A9 antibody. A second monoclonal antibody (C8) was reactive with intact GBS but did not precipitate soluble antigen in bacterial extracts. In contrast with what has been shown for polyclonal rabbit anti-group B antiserum, neither antibody was significantly inhibited in binding or precipitation assays by high concentrations of free rhamnose or other monosaccharides of carbohydrates found in group B antigen. Rhamnose, the most abundant carbohydrate of the group B antigen, does not appear therefore to be an immunodominant determinant in the binding of A9 or C8 antibody. The epitopes of both monoclonal antibodies are exposed on the surface of live as well as heat-fixed GBS cells. A9 antibody-coated latex particles were compared with a commercially available polyclonal latex agglutination reagent and shown to be equally sensitive and specific in the detection of soluble group B antigen in urine and cerebrospinal fluid from patients with GBS infections. Because of its uniformity and defined antigen specificity, which includes reactivity with all five serotypes of GBS, A9 antibody offers the potential of an improved immunodiagnostic reagent for the identification of GBS.
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Infections produced by group B streptococci (GBS) are among the leading causes of bacteremia and meningitis in neonates, with 12,000 to 15,000 cases reported annually in the United States (1) . Because of the fulminant nature of early-onset infections and the potential for serious sequelae produced by GBS meningitis, diagnosis of GBS infections has focused on methods for the rapid detection of circulating bacterial capsular polysaccharides present in body fluids. Latex agglutination, counterimmunoelectrophoresis (CIE), and, more recently, enzyme immunoassay have been used to identify GBS group-or type-specific antigen in the cerebrospinal fluid (CSF), urine, or serum of infected individuals (2, 3, 9, 19, 22, 27) .
Both group-and type-specific cell wall antigens are used in the immunological identification of GBS. Type-specific antigen, thought to be the outermost of these cell wall carbohydrates, has been characterized most extensively for type III tPresent address: 125 Hardy Rd., Westbrook, ME 04092. and also for type Ia, Ib, and II GBS. Type antigens have been shown to contain variable amounts of galactose, glucosamine, heptose, and sialic acid (4, 10, 11, 24, 28) . Group B antigen, in contrast, is a rhamnose-rich polymer (rhamnose-N-acetylglucosamine-galactose, 5.0:1.2:1.0) with properties less well characterized than those of the type antigens (4, 6 Ascites fluid production and purification. Mice primed intraperitoneally with pristane (2,6,10,14-tetramethylpentadecane) each received 5 x 106 hybridoma cells suspended in RPMI 1640 via intraperitoneal injection. Ascites fluid was removed during the subsequent 14 to 30 days, centrifuged, pooled, and frozen at -80°C until processing. Purification of monoclonal antibodies was performed by precipitation with a 45% saturated ammonium sulfate solution followed by dialysis against 0.05 M Tris-hydrochloride-0.125 M NaCl (pH 7.5). Dialyzed, partially purified preparations of monoclonal antibodies were stored at 4°C in the presence of 0.1% sodium azide. Protein determinations were made by the Lowry procedure, using bovine serum albumin as the standard (16) .
Radioactive binding assay. Heat-treated cell suspensions (60°C for 60 min; 5% [wt/vol] in phosphatebuffered saline [PBS]) of streptococcal groups A, B, C, D, F, and G were used both in screening hybridoma cell culture supernatants for group B-specific monoclonal antibodies and in binding experiments involving purified ascites antibody. Two-step binding assays were performed in 96-well flexible microtiter plates by the sequential addition per well of 50 ,ul of 5% bacterial suspension, 50 Fl of a 1:2 dilution of normal rabbit serum in PBS, and 50 pl of tissue culture supernatant or 2 to 5 ,u of ascites fluid. The mixtures were incubated at 25°C for 60 min, centrifuged at 100 x g for 15 min, and washed three times with 150 ,ul of PBS containing 0.3% bovine serum albumin (Sigma). Pel Immunoprecipitin assays. Ouchterlony double-diffusion and CIE tests were performed with 1% agarose (SeaKem ME; Marine Colloids, Rockland, Maine) in 0.5 M sodium diethyl barbiturate-0.001 M EDTA (pH 8.6) buffer by established procedures (5). Immunoprecipitin bands were visualized after staining with 0.2% Coomassie brillant blue.
Latex particle agglutination tests. Monoclonal antibody-coated latex agglutination reagent was prepared by using polystyrene latex particles with a uniform diameter of 0.81 ,um (Dow Chemical Co., Indianapolis, Ind.) as described by Ward et al. (25) . Purified monoclonal antibody (0.5 mg/ml) diluted in 0.1 M glycine-O.9o sodium chloride (pH 8.2) (GBS) buffer was mixed in equal parts with a 2.5% suspension of latex particles, also in GBS buffer. After incubation at 37°C for 2 h, the mixture was diluted with an additional part of GBS buffer containing 0.1% bovine serum albumin and 0.15% sodium azide and stored at 4°C. A control latex reagent was prepared in a similar manner, using mouse monoclonal anti-human histocompatibility antigen A.2 (Atlantic Antibodies, Scarborough, Maine).
Agglutination testing was performed by adding 20 RI samples of CSF, serum, urine, or bacterial extract to 20 ,u1 of latex reagent applied to a glass slide. The drops were stirred with an applicator stick, and the extent of agglutination was recorded immediately and at 1 and 3 min after mixing, using a grade of 0 to 4+ as described by Neuman et al. (18) . Agglutination of 2+, in which some definite clumping was observed but the background remained cloudy, was considered the minimum endpoint of a positive reaction. Control latex was used to detect nonspecific agglutination produced by rheumatoid antiglobulins.
GBS antigen extraction and purification. Capsular group carbohydrate antigen was extracted by three established methods: hot HCI (14) , autoclaving (20) , and Streptomyces albus-lysozyme (26) treatment of bacterial cells. The various streptococcal strains used for these procedures were all harvested from liquidgrown cultures. Partially purified group B polysaccharide antigen was derived, by a modification of the method of Doran et al. (8) , from the culture supernatant of GBS strain 090R grown to stationary phase in Todd-Hewitt broth.
The supernatant from an 18-h culture was first filter sterilized (0.45-,um membrane), and the resulting bacterium-free growth medium was concentrated fourfold by using a stirred-cell pressure concentrator and a PM-10 membrane (Amicon Corp., Lexington, Mass.). After extensive dialysis against a 200-fold excess of distilled water, nucleic acids were removed by sequential addition of CaCl2 and absolute ethanol to final concentrations of 0.1 M and 25% (voL/vol), respectively. The resulting precipitate was removed by centrifugation, and ethanol was added to a final concentration of 80%Xo (vol/vol) . The capsular polysaccharides precipitated by this procedure were collected by centrifugation, dissolved in distilled water, and dialyzed overnight at 4°C against water. Capsular antigens present in this mixture were then partially purified by chromatography on Sepharose CL-6B, equilibrated, and eluted with 0.0025 M NaPO4-0.0375 M NaCl (pH 7.2). Column eluate was monitored by measurement of the optical density at 280 nm, and fractions containing antigen reactive with CDC anti-group B antiserum by CIE were pooled and used for the immunoprecipitation studies described above. The rhamnose content of purified group B antigen was determined by the sulfuric acid-cysteine method of Dische and Shettles (7).
Antisera and latex reagents. Streptococcal groupspecific antisera were obtained from CDC. The antigroup B antiserum used was lot no. 770500. A commercially available group B latex agglutination reagent was obtained from Burroughs Wellcome Co., Research Triangle Park, N.C. RESULTS GBS-specific monoclonal antibodies. Two hybridomas, GBS III/3-5AC8 and GBS II/4-1OBA9, each producing antibody with specificity for antigenic determinants common to group B streptococci, were identified in separate fusions of NSI cells and GBS-primed BALB/c splenocytes. Preliminary screening of postfusion culture supernatants in hybridizations involving GBS type II-or GBS type III-immunized mice revealed 29 of 99 and 7 of 49 hybridoma-containing wells, respectively, which had antibody reactive against GBS in a bacterial cell-binding assay. Further selection for hybridomas producing antibody with group B specificity was made by screening culture supematants against representative Lancefield group A, C, D, F, and G organisms. Two anti-group B-specific antibodyproducing hybridomas, one from each fusion, were identified and cloned, and their antigenbinding properties were characterized. Table 1 shows the reactivity in an indirect binding assay of tissue culture supematant and purified ascites antibody derived from each of these hybridomas. An eightfold or greater binding was noted in reactions of both monoclonal antibodies with heat-treated cells of representative group B as compared with non-group B streptococci. The specificities of C8 and A9 antibodies for group B cells, furthermore, were similar with cell culture supernatant and ascites-derived antibodies. Both antibodies were shown in separate experiments ( (10 ,ul) in the center well was reacted with 10-or 20-,ul samples of group B strain 090R extracts prepared by enzyme (S. albus and lysozyme) (wells 1 and 2), hot HCI (wells 3 and 4), or autoclave (wells 5 and 6) procedure.
of representative Lancefield group A, B, C, D, F, and G organisms were reacted with purified ascites antibody in gel diffusion. Extracts of each of the streptococcal strains tested were shown to contain group-specific antigen, as evidenced by precipitin reactions between the extracts and their homologous rabbit anti-group antisera (Fig. 4) . Immunoprecipitation by A9 antibody, however, was observed only in diffusion against group B extract. The group B specificity of A9 antibody was further confirmed in immunodiffusion reactions with 42 clinical isolates of streptococci (5 group (Table 3) . Clinical samples from patients with bacteriologically confirmed GBS infections were obtained from Patricia Bromberger, Veteran's Hospital, San Diego, Calif. Samples of urine and CSF which had been stored frozen from a previous study of group B antigen detection (3) were reexamined, using A9 monoclonal antibody, by the latex agglutination and CIE methods. A9 latex reagent detected in vivo circulating group B antigen in both urine and CSF samples (Table 3) . Approximately the same degree of sensitivity in antigen detection was observed with A9 and Streptex rabbit antiserum reagents. A9 antibody reacted by CIE to identify group B antigen in most of the same patient samples ( Table 3 ). The greater number of positive samples detected by latex agglutination reflects the greater sensitivity of this technique and was similar for both A9 and polyclonal antibodies.
Differences observed in CIE antigen detection between A9 and CDC anti-group B antibody in three urine samples (patients 2, 3, and 4) raised concern that in vivo circulating group B carbohydrate might not be antigenicaily equivalent in different patient samples. CIE determinations were repeated for these patient samples with the addition of 4% T-70 dextran to the agarose support medium to improve the sensitivity of bacterial polysaccharide detection (21) . In the case of the urine sample from patient 2, the addition of dextran produced a precipitin reaction with A9 antibody, whereas agarose without dextran yielded no reaction. In contrast, however, urine from patient 4 showed no antigen, as detected by A9 antibody, even with added dextran. Although qualitative differences in circulating antigen might be inferred from differences in CIE reactivity between A9 and rabbit anti-group B antisera, soluble group B carbohydrate was nevertheless detected by both monoclonal and polyclonal reagents in the latex agglutination test. Differences in CIE reactivity between A9 and rabbit antibodies in a limited number of samples may reflect either differences in the precipitating properties of circulating group antigen or extraneous effects on the precipitation produced by sample variability. The antigenic form of circulating group B carbohydrate in patient urine and CSF would appear, however, to retain the epitope recognized by monoclonal A9 antibody. DISCUSSION In this report, we describe two monoclonal anti-group B streptococcal antibodies with specificities for surface antigens common to the various serotypes of GBS. Because of its immunoprecipitating properties, A9 antibody was shown to react specifically with group B carbohydrate antigen. The specificity of A9 antibody for an epitope on group B antigen in which The demonstrated binding of A9 antibody to group B streptococcal cells, live or heat fixed, revealed an interesting property concerning the topology of the group B antigen. A previous report, in which GBS were stained with ferritinlabeled rabbit anti-group B or anti-type antigen antibodies, indicated tha type antigen, but not group antigen, is accessible to external antibody binding (12) . A conclusion from these observations was that group B antigen is located internal to type-specific antigen on the surface of GBS cells, an observation consistent with the greater significance of anti-type antigen antibodies in protective immunity to GBS infections (15) . Evidence from results with A9 antibody binding, in contrast, showed that portions of the group B antigen were exposed for antibody interaction, indicating that aspects of the group B antigen were not masked by the outermost type antigen layer. The binding of A9 and possible C8 antibody to the surface of intact GBS cells suggests that antibodies which recognize such aspects of the group B antigen might play a role in immunity to GBS infections. This possibility is currently being investigated.
Applications of A9 monoclonal antibody to clinically useful GBS identification procedures showed that monoclonal reagents were directly comparable to conventional diagnostic antisera in bacterial identification and group B antigen detection procedures. The specificity of A9 antibody for a determinant which is both common to VOL. 16, 1982 on October 26, 2017 by guest http://jcm.asm.org/ Downloaded from all group B serotypes and present on in vivo circulating antigen suggests that this antibody would be particularly suited for the development of tests for the early detection of GBS infection. Monoclonal antibodies, such as A9, that are uniform, plentiful, and highly specific without immunoabsorption also offer the promise of more reliable and potentially standardized reagents for a variety of diagnostic assays.
